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Background: Variations in the GABRA2 gene, encoding α2 subunits of GABAA
receptors, have been associated with risk for addiction to several drugs, but the
mechanisms by which variations in non-coding regions of GABRA2 increase risk for
addictions are not understood. Mice with deletion of GABRA2 show deficits in the
ability of psychostimulants to facilitate responding for conditioned reinforcers, offering
a potential explanation.
Methods: We report human and mouse studies investigating a potential endophenotype
underlying this association. Healthy human volunteers carrying either cocaine-addiction
“risk” or “protective” GABRA2 single nucleotide polymorphism (SNPs) were tested for
their subjective responses to methylphenidate, and methylphenidate’s ability to facilitate
conditioned reinforcement (CRf) for visual stimuli (CS+) associated with monetary
reward. In parallel, methylphenidate’s ability to facilitate responding for a visual CRf was
studied in wildtype and α2 knockout (α2−/−) mice.
Results: Methylphenidate increased the number of CS+ presentations obtained by
human subjects carrying protective, but not risk SNPs. In mice, methylphenidate
increased responding for a CS+ in wildtype, but not α2−/− mice. Human
subjects carrying protective SNPs felt stimulated, aroused and restless following
methylphenidate, while individuals carrying risk SNPs did not.
Conclusion: Human risk SNP carriers were insensitive to methylphenidate’s effects
on mood or in facilitating CRf. That mice with the gene deletion were also
insensitive to methylphenidate’s ability to increase responding for CRf, suggests a
potential mechanism whereby low α2-subunit levels increase risk for addictions.
Circuits employing GABAA-α2 subunit-containing receptors may protect against risk for
addictions.
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INTRODUCTION
Gene variants of the GABRA2 gene, encoding α2 subunits
of GABAA receptors, have been associated with risk for
addiction to several drugs, including alcohol (Covault et al.,
2004; Edenberg et al., 2004; Enoch et al., 2006) and cocaine
(Dixon et al., 2010; Enoch et al., 2010). The neurobiological
mechanisms by which variations in non-coding regions of
GABRA2 translate into risk for addictions are not understood,
but a potential explanation comes from rodent studies showing
high density of α2-containing GABAA receptors in the
nucleus accumbens (Pirker et al., 2000; Dixon et al., 2010),
a brain area associated with reward and motivation and
implicated in drug abuse and addiction (Robinson and Berridge,
1993; Robbins and Everitt, 2007). Deletion of α2-containing
receptors in the mouse (α2−/− mice) reduces GABAergic
currents in accumbal medium spiny neurons (MSNs) by
about 30% (Dixon et al., 2010), and leads to impairments
in both psychomotor sensitization to cocaine (Dixon et al.,
2010) and the ability of cocaine to facilitate instrumental
responding for conditioned reinforcers (Dixon et al., 2010);
both phenomena are hypothesized to contribute to drug abuse
by facilitating incentive learning (Robinson and Berridge,
1993; Parkinson et al., 1999; Le Merrer and Stephens, 2006).
Thus α2-containing receptors are both appropriately located
to influence addiction-related behaviors, and manipulation of
their expression influences the motivational consequences of
cocaine.
Nevertheless, it is unknown whether human gene-variants
conferring increased risk for addiction alter expression of α2-
containing GABAA receptors, and through this mechanism
affect incentive learning. Accumbens activation during reward
anticipation is enhanced in human adolescents carrying
the GABRA2 risk G allele of rs279858 (Heitzeg et al.,
2014), suggesting an effect on incentive processing consistent
with reduced inhibition of accumbens MSNs, but evidence
associating risk variants with changed α2 expression is
inconclusive (Haughey et al., 2008). The rs299858 single
nucleotide polymorphism (SNP) creates a change in the triplet
codon for amino acid residue 132, but does not change the
protein sequence. This and other intronic SNPs in the vicinity
(including rs279871 and rs279845 studied here) may tag a region
that changes the stability/expression of the mRNA and thus
alter expression of the GABRA2 gene. Some support for this
interpretation comes from a recent report (Lieberman et al.,
2015) that GABRAA2mRNA in neural cell cultures derived from
rs279858∗C allele (risk allele) carriers is lower. The question
thus remains whether, and to what extent, the mouse behavioral
findings provide a clue as to how the human GABRA2 genetic
variations confer risk for addictive behavior.
To address this question, we carried out parallel studies
in humans and mice to establish the extent to which the
findings from α2−/− mice inform those from humans with
addiction-associated GABRA2 gene variants. Integrating data
from animal and human experiments is often hindered by
the use of different experimental measures in the two species
(Stephens et al., 2010). In order to integrate our mouse and
human experiments, we developed a human homolog of the
conditioned reinforcement (CRf) measure we use in mice,
allowing us to draw close parallels between data obtained
from the two species. We then studied the ability of a
psychostimulant drug, methylphenidate, to facilitate CRf in
mice (WT and α2−/−) and humans (risk and protective
genotypes).
MATERIALS AND METHODS
Human Study
Participants
Healthy male and female volunteers (n = 397), aged 18–40
years, were recruited from staff and students at the University
of Sussex. Buccal swabs were collected, DNA extracted, and
genotypes determined commercially (KBiosciences; Hoddesdon,
UK)1, using a proprietary fluorescence-based competitive allele-
specific polymerase chain reaction (KASPar).
Classification of Participants According to Genotype
Genotyping of five SNPs allowed identification of subjects
carrying risk or protective alleles, based on SNPs and a haplotype
associated with cocaine addiction in our previous study (Dixon
et al., 2010). Allocation of specific genotypes to groups is
outlined on Table 1. The risk group possessed risk alleles G
(rs279871) and A (rs279845) in homozygosity, but not the
protective allele T (rs894269) nor the protective haplotype
(rs894269:T, rs2119767:T, rs929128:G). The protective genotype
group consisted of a combination of genotypes: They were
homozygous for absence of the risk alleles (and carrying at
least one copy of the protective SNP, or heterozygous for
the risk alleles and homozygous for the protective SNP and
haplotype). One of our risk SNPs, rs279871, is in 100% linkage
disequilibrium with rs279858 widely reported by other groups
(see ‘‘Discussion’’ Section). Twenty-six participants (15 female)
with the risk genotype and 23 participants (14 female) with
the protective genotype, aged 18–30 (mean 20.7) years, in
good health, and taking no medication (with the exception
of contraceptive pills), completed the following questionnaires:
Alcohol Use Questionnaire (AUQ; Mehrabian and Russell,
1978), Drug Use Questionnaire (Duka et al., 2003) including
smoking (cigarettes per day), the National Adult Reading
Test (NART; Nelson and O’Connell, 1978) to evaluate verbal
IQ, and the State-Trait anxiety scale (Spielberger et al.,
1970).
Additional requirements for inclusion were that body
mass index was in the range 18–28; blood pressure was
<140/90 mmHg; breath alcohol concentration was 0.00
mg/l; participants were physically and mentally healthy
with no alcohol or drug dependence, glaucoma, tinnitus
(or family history of tinnitus); female participants were not
pregnant (assessed by urine pregnancy test), or breastfeeding.
Participants were required to avoid alcohol for 12 h, and
recreational drugs for 5 days prior to the test session.
1www.kbioscience.co.uk
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TABLE 1 | Participant genotypes (∗Protective haplotype is rs894269 (T), rs2119767 (T), rs9291283 (G)).
SNPS/haplotypes Risk Protective
rs279871 G:G A:A A:A G:A
rs279845 A:A T:T T:T T:A
rs894269 C:C T:T T:C T:T
∗Protective Haplotype 0 copies 2 copies 0/1 copy 2 copies
Methylphenidate group n = 12 n = 3 n = 6 n = 2
Placebo Group n = 14 n = 1 n = 11 n = 1
The combination of genotypes selected for each SNP/haplotype are shown and number of participants for each genotype allocated to drug groups.
Ethical approval was obtained from the University of
Sussex ethics committee, and participants gave written
informed consent. Participants received £6 per hour or course
credits.
Design
In a double-blind, placebo-controlled, between-subjects design,
participants from each genotype group were randomly allocated
to receive 20 mg methylphenidate or a matched placebo.
Methylphenidate capsules contained 2× 10 mgmethylphenidate
tablets (Medikinetr) inside a gelatine capsule. Placebo capsules
were identical but filled with 20 mg sugar. The dose of 20 mg was
chosen based on previous studies with healthy human volunteers
(e.g., Elliott et al., 1997; Roehrs et al., 2004).
Procedure
Experimental sessions lasted 5–6 h. Participants first underwent
Pavlovian training, which revealed no differences between
groups, before receiving the allocated treatment. To ensure
participant safety, BP was measured 30 míns, and 90 mins post-
drug (to coincide with peak methylphenidate plasma levels).
Visual-analog scale (VAS) mood measures were assessed at 90
min. Immediately following the mood measures, the CRf test
phase was carried out. At the completion of testing, BP was
required to be <140/90 mmHg before participants were allowed
to depart.
Materials
Visual Analog Scales (VAS) of Drug Effects
A set of 9 × 100 mm VASs were labelled with adjectives related
to effects of stimulant drugs (‘‘irritable’’, ‘‘stimulated’’, ‘‘alert’’,
‘‘restless’’) intermixed with adjectives related to other drug effects
(‘‘contented’’, ‘‘anxious’’, ‘‘lightheaded’’, ‘‘relaxed’’, ‘‘tired’’). The
adjectives were anchored at each end with ‘‘not at all’’ and ‘‘very
much’’.
Profile of Mood States (POMS; Mcnair et al., 1971)
Seventy-two mood-related adjectives, rated on 5-point scales
(‘‘not at all’’ (0) to ‘‘extremely’’ (4)), provided eight factors:
Anxiety, Fatigue, Depression, Anger, Vigour, Confusion,
Friendliness, and Elation. For evaluating methylphenidate effects
we used two composite factors: Arousal = (Anxiety + Vigour)
− (Fatigue + Confusion), and Positive Mood = (Elation −
Depression; de Wit and Doty, 1994). Only the two composite
factors were evaluated for this study.
Conditioned Reinforcement Behavioral Task
During Pavlovian discrimination training (Austin and Duka,
2010), participants learned to associate two visual stimuli
(Figure 1A), randomized across participants, with either 10p
monetary reward (CS+), or no reward (CS−). The task was
programmed using E-Prime v1.1 (Psychology Software Tools;
Philadelphia, PA, USA) and presented on a PC. There were 50
CS+ trials and 50 CS− trials presented in blocks of 20 trials
(10 CS+ and 10 CS−). At the start of the task the following
instructions were presented on screen: ‘‘Each trial will begin with
a fixation cross (+) in the center of the screen. Next, you will
see a picture. Then you will be asked how likely you are to gain
10 pence. Rate the likelihood of gaining 10 pence on a scale of
1–9 (1 = unlikely, 5 = don’t know, 9 = likely). Press the space
bar to begin’’. In each trial a visual stimulus was displayed in
the center of the screen for 3 s, followed in by an expectancy
question which read ‘‘How likely are you to gain 10p? (1 =
unlikely, 5 = don’t know, 9 = likely)’’. After participants had
provided their response, feedback was provided in the center
of the screen for 2 s. On 90% of CS+ trials feedback consisted
of the text ‘‘You gain 10p’’ and 10% of the time no feedback
was provided. On 90% of CS− trials feedback consisted of the
text ‘‘You win nothing’’ and 10% of the time no feedback was
provided. After 20 trials participants were instructed to move
90 pence (to represent their ‘‘winnings’’) from a tin located to
the left of the computer keyboard into an identical tin marked
‘‘Your money tin’’ located to the right hand side of the computer
keyboard.
During the test for CRf (Figure 1B for an illustration)
responses to access the stimuli (CS+ and CS−) were recorded in
the absence of monetary reinforcement. CRf was tested using two
tasks, but only the task newly developed to resemble the mouse
task (repeated presses CRf) is presented. The other task (press
and hold CRf) was amodification ofMucha et al.’s (1998) task; no
effects of drug or genotype were found and the findings are not
reported here. The two versions were allocated in randomized
sequence, but no effect of sequence in any of the key variables
was found.
The instructions shown on screen were: ‘‘Now at the start of
the trial you will hear a tone. Then you can view pictures by
repeatedly pressing one of the keys marked ‘‘view’’. When you
stop pressing the key the picture will disappear. You can look
at whichever picture you choose for as long as you choose, by
pressing the appropriate key. You may switch between pictures
if you wish. Press the space bar to begin’’. Then followed 2 × 1
min blocks during which a neutral tone was delivered binaurally
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FIGURE 1 | Visual stimuli (A) used during the Pavlovian conditioning for
the participants to learn associations with either monetary reward
(CS+) or with absence of reward (CS−). Description of CRf testing (B).
Participants had to press repeatedly either the key associated with the CS+ or
the key associated with the CS− presentation. A mild tone prompted them to
start pressing if they wanted. Absence of pressing for a time window of 500
ms made the stimulus disappear.
through headphones. The ‘‘Q’’ and ‘‘P’’ keys of the computer
keyboard were marked clearly with the word ‘‘VIEW’’, and upon
pressing one of these keys at a rate of at least one press per
500 ms, the tone ceased, and CS+ or CS− was displayed in
the center of the screen. If participants did not respond within
a window of 500 ms, the stimulus disappeared. CS+ and CS−
were allocated to the ‘‘Q’’ or ‘‘P’’ key in counterbalanced order
across participants. Time spent viewing each of the stimuli was
recorded. In addition, the number of times each stimulus was
viewed was recorded.
During the CRf measurement participants could alternate
between two keys, but either stimulus was kept in view by
repeated presses on the designated key, providing a variable
‘‘duration of CS presentation’’. If there were no presses within
500 ms the stimulus disappeared until reinstated by a further
press, providing a variable ‘‘number of CS presentations’’.
Thus, whereas duration of CS presentation was the measure of
conditioned incentive value expressed via capture of attention,
the number of CS presentations indicates motivation to reinstate
the salient stimulus.
Mouse Study
Animals. Wildtype (WT; n = 12) and knockout (α2−/−; n = 12)
male mice were bred from heterozygous pairings andmaintained
on a mixed 50% C57BL/6J / 50% 129SvEv background (Dixon
et al., 2008). Animals were housed under a 12 h light/dark cycle
(lights on at 7.00 AM), with controlled temperature (≈ 21◦C)
and humidity (≈ 50%). Water was available ad libitum within
the homecage, but food was restricted to maintain body weight
at approximately 85% of free-feeding weight. All experiments
were carried out under the authority of the UKAnimal (Scientific
Procedures) Act, 1986, following institutional ethical approval.
Drugs. Methylphenidate hydrochloride (Sigma, UK) was
dissolved in 0.9% w/v saline and administered i.p. at a volume
of 10 ml/kg.
Methylphenidate-potentiated Conditioned
Reinforcement
Pavlovian Conditioning
To test the ability of the α2 KO mice to form a Pavlovian
association, food-deprived WT and KO mice (n = 12) were
trained in standard conditioning chambers (MedAssociates, St.
Albans, VT, USA) to retrieve sweetened food pellets (20 mg;
Noyes precision pellets, Formula P, Research Diets, Inc., New
Brunswick, NJ, USA), for 11 daily sessions. During each 60
min session, a 10 s (conditioned) stimulus was paired with
food pellet delivery (CS+), commencing 5 s before food pellet
delivery. A second stimulus (CS−) was also presented for 10
s with no food delivered. Sixteen of each CS were presented
in a randomized order on a variable time schedule of 100 s.
The conditioned stimuli consisted of two flashing stimulus lights
(1 Hz) or a constant tone (2.9 kHz), counterbalanced between
CS+ and CS−. The stimulus lights were located above and to
either side of the food magazine, with the tone generator directly
above the magazine. The percentage of nose pokes into the food
magazine during the CS+ and CS− were recorded as a measure
of discriminated approach.
Conditioned Reinforcement. Following training, two nosepoke
apertures were introduced into the chambers, located in the wall
opposite the food magazine. During a 60 min session, nosepokes
into one aperture (counterbalanced) resulted in illumination of
the CS+ for 1 s whilst responses into the alternative aperture
resulted in a 1 s presentation of the CS−. No food reinforcers
were delivered during the CRf session. The ability of the cues
to act as conditioned reinforcers was assessed as higher rates
of responding in the CS+ associated aperture compared to the
CS− associated aperture. Animals that did not reach criterion for
CRf (>75% CS+ nosepoke responses) were excluded from drug
testing.
Methylphenidate-potentiated CRf. Mice that had acquired
CRf (WT (n = 11); α2−/− (n = 8)) were injected at 2-
day intervals with methylphenidate (0, 0.3, 1.0 and 3.0
mg/kg) using a counterbalanced design, and tested for CRf
immediately following drug administration. Drug-free Pavlovian
conditioning (retraining) sessions were conducted on the days
between test sessions.
Methylphenidate Locomotor dose Response
Apparatus. To assess genotype differences in the stimulant
effects of methylphenidate, locomotor activity was assessed using
16 black Perspex, circular runways (internal diameter, 11 cm;
external diameter, 25 cm; height, 25 cm), as described previously
(Dixon et al., 2010).
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Methylphenidate locomotor activation. WT and α2−/− mice
(n = 12 per group) were habituated to the locomotor runways for
60min on two consecutive days. Subsequently, they were injected
with methylphenidate (0, 0.3, 1.0 and 3.0 mg/kg) daily, using
a counterbalanced design, and locomotor activity measured
immediately post-injection for 60 min.
Statistical Analysis
Human: Baseline questionnaire data were analyzed using one-
way ANOVAwith genotype and drug group as a between-subject
factors. Mood measurements were analyzed using repeated
measures ANOVA with time (pre- vs. post-drug) as within-
subject and genotype and drug as between-subject factors. CRf
dependent variables were analyzed using mixed ANOVAs with
stimulus (CS+ vs. CS−) as within, and drug and genotype as
between-subject factors.
Mouse: Acquisition of Pavlovian conditioning was assessed by
calculating the percentage of nose pokes per minute into the food
magazine during the CS presentation. These data were analyzed
using a 3-factor mixed ANOVA, with genotype as a between-
subject, and session and CS type as within-subject factors. Effects
of methylphenidate and genotype on CRf were analyzed using a
mixed ANOVA in which the factors dose and nosepoke aperture
(CS+ or CS−) were within-subject and genotype between-subject
measures.
Methylphenidate effects on locomotor activation (distance
travelled) were assessed using a 2-factor mixed ANOVA, with
genotype as a between-subject and drug dose as a within-subject
factor. Post hoc paired-samples t-tests compared the test dose to
vehicle.
RESULTS
Human Studies
Group Characteristics and Baseline Measurements
Table 2 shows group characteristics, indicating no difference in
age, verbal IQ, or other characetristics.
Pavlovian conditioning led to an increase in expectancy of
reward in the presence of CS+ vs. CS− (data not shown; main
stimulus effect: F1,41 = 340.8; p < 0.001), which increased
over trials (block by stimulus interaction (F4,164 = 5.573; p <
0.001)), showing progression of learning. All participants already
showed learning in block 1 of trials. No genotype effects, or
interactions involving genotype reached significance (F values<
2.345; p> 0.1).
Methylphenidate Mood Effects
Methylphenidate increased restlessness, as measured by VAS,
and arousal, as measured by the Profile of Mood States (POMS),
in all participants (time by drug interaction, F1,45 = 7.334,
p = 0.010 and F1,45 = 8.167, p = 0.006 respectively); these
methylphenidate effects were greater in the protective vs. the
risk genotype (genotype by drug by time interaction, ‘‘restless’’
F1,45 = 6.335, p = 0.015 (Figure 2A) and ‘‘arousal’’ F1,45 =
7.407, p = 0.009 (Figure 2B), respectively). VAS measures
of feeling ‘‘stimulated’’ showed also larger increases following
FIGURE 2 | Subjective ratings in Visual Analog Scale (VAS) restless (A),
in the composite score “Arousal” from the Profile of Mood States
(POMS; B) and in Visual Analog Scale stimulated (C). Data (mean ±
SEM) are given for risk and protective genotypes and for pre and post
methylphenidate or placebo treatments. A significant drug by genotype by
time interaction was attributable to an increase in the ratings under
methylphenidate in comparison to placebo in the protective, but not in the risk
genotype. *p < 0.05 compared to pre drug (post hoc paired t-tests).
methylphenidate in the protective vs. the risk genotype (genotype
by drug by time interaction (F1,45 = 7.087, p = 0.011; Figure 2C).
No effects on measures for ‘‘positive mood’’ (composite factor
in POMS) or VAS scales ‘‘alert’’, ‘‘irritable’’, ‘‘contended’’,
‘‘anxious’’, ‘‘lightheaded’’ and ‘‘relaxed’’ were found (data not
shown).
Methylphenidate-Potentiated Conditioned
Reinforcement
Following Pavlovian pairings of visual stimuli with monetary
reward, subjects responded to earn access to the stimuli. The
number of CS presentations obtained (F1,45 = 17.69; p < 0.001;
Figure 3A) and the total duration of CS presentations (F1,45 =
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FIGURE 3 | Number of CS presentations (A) and duration of CS
presentations (B) for the CS+ and CS− in the 2 min of CRf
measurement. Data (mean ± SEM) are given for risk and protective
genotype and for methylphenidate (MPD) and placebo (Pla) treatments. A
significant drug by genotype by stimulus interaction was found for the number
of CS presentations due to an increase in the number of CS+ presentations
under methylphenidate in the protective but not in the risk genotype. A
significant drug by genotype by stimulus interaction was found also for the
duration of CS presentations, indicating a decrease in duration of CS+
presentation under methylphenidate, in comparison to placebo, in the risk but
not in the protective genotype.
47.7; p < 0.001; Figure 3B) were greater during CS+ than
CS− trials, indicating that the CS+ had acquired (conditioned)
reinforcing properties, but there were no genotype differences.
Methylphenidate increased the number of CS+ presentations
in the protective, but not in risk genotypes (Figure 3A). A
significant 3-way (stimulus by drug by genotype) interaction
(F1,45 = 5.597; p = 0.022) was explained by an increase in the
number of earned CS+ presentations following methylphenidate
vs. placebo treatment in the protective (F1,21 = 4.657, p = 0.043),
but not the risk genotype (F1,24 = 0.781, p = 0.386). For CS
presentation duration, a significant 3-way interaction (F1,45 =
6.77; p = 0.013) was attributable to a drug by stimulus interaction
in the risk (F1,24 = 6.19; p = 0.020), but not protective (F1,21 = 1.33;
p= 0.26) genotype, withmethylphenidate decreasing the duration
of CS+ presentations in the risk genotype (Figure 3B).
In the protective genotype group, three participants were
homozygous for the protective genotype but heterozygous for the
two risk alleles. We therefore carried out an additional statistical
analysis using only those individuals in the protective genotype
group who were homozygous in not possessing the risk variant.
The statistically significant three way interaction for number
of CS presentations and total duration of CS presentations
remained significant (F1,42 = 4.76; p = 0.035 and F1,42 = 5.68; p =
0.022, respectively).
To examine whether the methylphenidate-induced changes
in mood varied systematically with the CRf performance
(duration of stimulus presentation and number of stimulus
presentations), post hoc bivariate Pearson correlations were
performed between mood ratings and CRf performance,
separately for the methylphenidate and the placebo groups. For
this purpose baseline VAS ratings ‘‘stimulated’’ and ‘‘restless’’ as
well as POMS ‘‘arousal’’ ratings were subtracted from post-drug
ratings; duration and number of CS− presentations during CRf,
were subtracted from the respective values of CS+.
As expected, significant correlations were found only for the
methylphenidate group. Enhanced feelings of ‘‘stimulated’’ were
correlated with the number (r = 0.463, p = 0.026) and the
duration (r = 0.602, p = 0.002) of CS+ over CS− presentations.
Duration of presentation of CS+ over CS− increased also with
increased feelings of ‘‘restless’’ (r = 0.480, p = 0.02).
Mouse
Methylphenidate-Potentiated Conditioned
Reinforcement
Pavlovian conditioning. Figure 4A illustrates that both α2−/−
and WT mice approached the food receptacle equally following
onset of the CS+ (main effect of session: F10,220 = 32.079, p <
0.001; session by genotype interaction: F10,220 = 0.731, p = 0.695),
confirming that constitutive α2 deletion has little effect on simple
discriminative Pavlovian conditioning (Dixon et al., 2010).
Conditioned Reinforcement. On the initial test to verify CRf,
mice of both genotypes readily and equally learned to nose-poke
to preferentially obtain access to the reward-associated visual
cue (Figure 4B; main effect of nose-poke, F1,22 = 19.604, p <
0.001; nosepoke by genotype interaction, F1,22 = 1.322, p = 0.263),
indicating that the CS+ had acquired conditioned reinforcing
properties. WT mice tended to nose-poke at higher rates (main
effect of genotype: F1,22 = 4.170, p = 0.053). One WT and four
α2−/− mice failed to meet criterion, and were excluded from
subsequent drug testing.
Methylphenidate-potentiated CRf. Under methylphenidate,
mice showed a dose-dependent change in discriminated nose-
poke responding that differed according to genotype (Figure 4C;
nose-poke by dose by genotype interaction: F3,51 = 4.276, p <
0.01). The genotype by dose interaction was present for responses
reinforced by CS+ (F3,51 = 4.336, p < 0.01) but not for CS−
reinforced responses (F3.51 = 1.015, p = 0.394). The dose-
dependent effect on responding for the CS+ was evident in
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FIGURE 4 | (A) Percentage of CS presentations resulting in entry to the food
magazine following presentations of CS+ or CS−, over successive training
sessions. There were no statistically significant differences in the rate at which
WT and α2−/− mice acquired the association between CS+ and food delivery
(nosepoke by genotype interaction: F(1,22) = 1.322, p = 0.263). (B) Numbers
of head entries into nose-poke detectors resulting in 1-s presentations of
either the CS+ or CS−. Although WT mice showed a tendency to make more
nosepokes into either CS+ or CS− holes (F(1,22) = 4.170, p = 0.053), there
were no significant interactions between genotype and CS, or in responding
for the CS+. (C) After methylphenidate treatment, mice showed a dose
dependent change in nosepoke responding that differed according to
genotype (nosepoke ∗ dose ∗genotype interaction: F3,51 = 4.276, p < 0.01).
This effect was attributable to CS+ responses (dose∗genotype interaction:
F3,51 = 4.336, p < 0.01) but not the CS− (dose*genotype interaction: F3.51 =
1.015, p = 0.394). The dose dependent effect of responding on the CS+ was
evident in WT (F3,30 = 7.286, p < 0.01) but not in the α2−/− mice (main effect
of dose: F3,21 = 0.127, p = 0.943). ∗ indicates significant differences from the
vehicle condition in WT mice. (D) Methylphenidate increased locomotor
activity in a dose-dependent manner (F3,66 = 7.825, p < 0.001),
independently of genotype. ∗ indicates significant differences from the vehicle
condition. MPD (Methylphenidate).
WT mice (main effect of dose: F3,30 = 7.286, p < 0.01), whilst
methylphenidate had no effect in α2−/− mice (F3,21 = 0.127,
p = 0.943). In the WT mice, paired sample t-tests comparing
methylphenidate to vehicle revealed a significant decrease in CS+
responses at 0.3 mg/kg (t10 = 3.862, p < 0.01) and a significant
increase at 3 mg/kg methylphenidate (t10 =−3.047, p< 0.05).
Methylphenidate Effects On Locomotor Activity
Figure 4D illustrates that methylphenidate increased locomotor
activity in a dose-dependent manner (main effect of dose F3,66 =
7.825, p < 0.001), but that there were no genotype differences in
locomotor activity (F1,22 = 0.002, p = 0.963), or drug by genotype
interactions (F3,66 = 0.573, p = 0.635).
DISCUSSION
We and others have previously reported an association between
variants of the GABRA2 gene, encoding the α2 subunit of
GABAA receptors, and human cocaine addiction (Dixon
et al., 2010; Enoch et al., 2010). Since deleting α2-GABAA
receptors in mice abolishes cocaine’s ability to facilitate
responding for a conditioned reinforcer, we suggested that
these findings might provide an approach to understanding
the association between GABRA2 variants and human cocaine
addiction (Dixon et al., 2010). In the current study, we
developed a novel measure of CRf in humans, based upon
the mouse task, which allowed us to demonstrate for the
first time that a psychostimulant facilitates responding for
CRf in non-addicted humans. Individuals carrying risk and
protective variants of the GABRA2 gene did not differ in their
performance on our task, indicating no effects of the gene
variants on incentive learning, consistent with our mouse
studies showing no effects of α2 deletion on CRf (Dixon
et al., 2010). However, the ability of the psychostimulant,
methylphenidate, to facilitate human CRf depended on genetic
makeup; while subjects carrying the addiction-protective
genotype showed methylphenidate-facilitated CRf, those
carrying risk alleles did not. These effects were paralleled in
mice; whereas at low dose methylphenidate mildly reduced
CRf responding in WT mice, at higher doses it markedly
facilitated CRf responding in WT but not α2−/− mice. The
reduction of responding for a conditioned reinforcer by 0.3
mg/kg methylphenidate was unexpected, but such a low dose
does not appear to have been tested previously. However,
facilitation of CRf by methylphenidate in WT mice has been
previously reported (Browne et al., 2014). Furthermore,
the lack of facilitation of CRf by methylphenidate in the
α2−/− mice resembles that previously reported for cocaine
(Dixon et al., 2010). Our mouse data also indicate that
the ability of methylphenidate to facilitate responding for
the conditioned reinforcer was not simply a consequence
of its motor stimulant properties since the locomotor
stimulant effects of methylphenidate did not differ between
genotypes.
A more likely account is that, in the human protective
genotype group and in WT mice, methylphenidate either
increased the value of the conditioned reinforcer, or facilitated
behavior elicited specifically by reward-associated cues, thus
facilitating responding to obtain presentations of the CS+.
Interestingly, in the risk group the value of the conditioned
reinforcer seemed to decrease under methylphenidate, inasmuch
as the CS+ presentation duration was decreased.
In addition to the altered methylphenidate effect on CRf in
the GABRA2 variants, we found higher subjective ratings of
methylphenidate-induced stimulation, restlessness and arousal
in individuals carrying the protective genotype compared to
those subjects expressing the risk genotype (Figure 2). Post
hoc correlations suggested that feeling ‘‘stimulated’’ under
methylphenidate was related to the number and duration of CS+
presentations under the drug. Since the subjective experience of
methylphenidate stimulant effects (‘‘high’’) paralleled its ability
to facilitate CRf performance, the feeling of ‘‘stimulated’’ may in
part reflect a subjective experience of a heightened motivational
state.
The predominant difference between the two genotypes
groups in our study is the presence or absence of two
‘‘risk’’ SNPs. SNAP analysis of data from the 1000 Genomes
Project (Johnson et al., 2008) shows our risk SNP rs279871
to be in 100% linkage disequilibrium with rs279858, while
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the other, rs279845, is in 92.9% LD with rs279858. rs279858
is the common risk SNP recognized across multiple studies
of addicted populations; it has been associated with alcohol
(Covault et al., 2004; Lappalainen et al., 2005; Fehr et al., 2006)
and cocaine abuse (Enoch et al., 2010), as well as childhood
conduct disorder (Dick et al., 2006) and impulsivity during
reward anticipation (Villafuerte et al., 2012). Thus variations
in this genomic area may alone be driving our genotype
differences. It may thus be relevant that some (Pierucci-
Lagha et al., 2005; Roh et al., 2011) but not all (Arias et al.,
2014) previous studies have found decreased effects of another
drug of abuse, alcohol, in measures of positive affect such as
stimulation, vigour and happiness, in carriers of the C-allele of
rs279858.
However, in order to try to increase our effect size within the
‘‘risk+’’ or ‘‘risk−’’ groups we enriched them with the absence
(in the risk+ group) or presence (in the risk− group) of the
putative protective SNP or haplotype identified in the previous
study (Dixon et al., 2010). This counts as a limitation in our study
as we cannot be sure whether the effect seen in the present study
is driven purely by the recognized risk SNP. Future studies should
establish the contributing genetic elements.
Inasmuch as risk genotype individuals have an increased
susceptibility for substance abuse or addictions, but reduced
effects of methylphenidate on both CRf, and feelings of
‘‘restlessness’’, ‘‘stimulated’’ and ‘‘arousal’’, our findings may
support accounts that drug taking occurs in order to overcome
either an individual’s innate relative insensitivity to reward
(Blum et al., 1996; Volkow et al., 1997) or a loss of reward
sensitivity as a consequence of ‘‘allostatic’’ adaptations arising
from previous drug abuse (Koob and Le Moal, 2008). In
keeping with that account, Volkow et al. (1997) reported
that cocaine addicts show a blunted cocaine ‘‘high’’ relative
to controls. Furthermore, individuals with low dopamine
D2 receptor levels and dopamine release show vulnerability
to develop addiction either in terms of high impulsive
traits (Trifilieff and Martinez, 2014) or decreased reward
sensitivity (Blum et al., 2014). Thus, addiction can be
understood as being associated with reduced sensitivity to
the stimulant subjective effects of abused drugs, including
both psychostimulants and alcohol. While in Volkow’s studies,
tolerance to cocaine’s subjective effects could have contributed
to the findings, our data are also consistent with drug abuse
being attributable to low reward-sensitivity (perhaps mediated
by dopamine systems; Blum et al., 1996, 2000), independent
of drug-experience. In the present study we found some
evidence (Table 2; DUQ) that individuals who were not
addicts, but carried a genetic risk for addictions, were more
likely than those carrying the protective genotype to use
drugs recreationally; however the effect was marginal (p =
0.067).
On the other hand, our data question the importance of
drug sensitization in the abuse of psychostimulants. Though
in the present report we did not examine the consequences
of alpha 2 knockout on behavioral sensitization in the mouse,
it would be remiss not to point out that we have previously
found such mice to show attenuated sensitization of cocaine-
induced psychomotor activation (Dixon et al., 2010). When
taken together with the present human data, these results may
thus suggest a dissociation between psychomotor sensitization
by cocaine and susceptibility to develop compulsive drug
seeking as seen in addicts. This conclusion seemingly challenges
Robinson and Berridge’s incentive sensitization theory of
addiction (Robinson and Berridge, 1993) but that finds support
from others (e.g., Ahmed and Cador, 2006). On the other
hand, such a conclusion oversimplifies psychomotor activation
both as a measure in the lab (see Robinson and Berridge,
1993) and as a theoretical mechanism in addiction. Indeed,
future preclinical studies exploring the involvement of alpha
2 in the effects of sensitization on more direct measures
of incentive motivation (e.g., performance on Pavlovian-
to-instrumental transfer, CRf or sign-tracking tasks) are
needed.
A recent report (Heitzeg et al., 2014) investigated incentive-
motivational circuitry in individuals carrying variations in the
GABRA2 gene. It is of considerable interest that in that
study, adolescents carrying the minor (risk) allele of rs279858
showed a heightened BOLD signal of accumbens during reward
anticipation in the Monetary Incentive Delay task, indicating
increased accumbal responsiveness to incentive cues. Although
the subjects in our study encompassed a broader age range, the
majority (n = 43) were in the 18–22 range. That risk genotypes
result in heightened accumbal response to conditioned incentives
is consistent with our earlier suggestion that manipulation
TABLE 2 | Participants characteristics given for each of the four groups (genotype protective (P) or risk (R) and placebo or methylphenidate treatment).
Variables P P R R Statistics
Placebo Methylphenidate Placebo Methylphenidate univariate
N = 12 N = 11 N = 14 N = 12 analysis Fs(1,45)
Age 20.7 ± 0.9 20.3 ± 0.5 20.7 ± 1.9 21.2 ± 1.0 Fs < 0.271, Ps > 0.607
NART (verbal IQ) 102.7 ± 2.9 105.9 ± 3.5 107.1 ± 3.0 105.3 ± 2.5 Fs < 0.705, Ps > 0.406
AUQ score 33.7 ± 5.2 36.3 ± 10.8 36.1 ± 6.3 37.3 ± 6.6 Fs < 0.067, Ps > 0.797
DUQ 1.0 ± 0.4 0.64 ± 0.3 1.3 ± 0.3 1.7 ± 0.4 Fs < 3.480, Ps > 0.069
Cigarettes per day 1.0 ± 0.9 0.68 ± 0.4 1.4 ± 0.9 2.7 ± 1.7 Fs < 1.139, Ps > 0.291
Trait anxiety 36.1 ± 2.3 40.9 ± 3.4 36.0 ± 2.0 36.7 ± 2.3 Fs < 1.254, Ps > 0.269
State anxiety 31.3 ± 2.1 38.9 ± 2.7 29.0 ± 1.6 30.2 ± 2.6 Fs < 3.483, Ps > 0.0697
No significant main group effects or between group interactions were found; NART, National Adult Reading Test; AUQ, Alcohol Use Questionnaire; DUQ, Drug Use
Questionnaire.
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of the GABAA α2 subunit in mice alters the ‘‘energizing’’
aspects of reward seeking (Dixon et al., 2014). Since GABAA
α2 subunits contribute importantly to GABAergic inhibition of
MSNs (Dixon et al., 2010; presumably the major source of the
accumbens BOLD signal, as they make up >90% of neurones
in ventral striatum), the heightened BOLD response in risk
allele carriers would be consistent with reduced α2 subunit-
mediated inhibition. The lack of effects of methylphenidate
in risk genotype carriers may thus reflect that in these
individuals, MSN responsiveness to reward signals is already near
maximal.
Thus, in keeping with the Heitzeg et al. (2014) report, a likely
location for the alpha2 subunits involved in the present dataset
is the ventral striatum, where we have shown that deletion of
alpha2 subunits leads to a 30% loss of GABAergic input to MSNs
of accumbens core (Dixon et al., 2010). It is well established that
ventral striatum core plays a central role in CRf (Everitt and
Robbins, 2005), and that facilitation of dopaminergic input to
this area lies at the basis of psychostimulant facilitation of CRf
(Kelley and Delfs, 1991). However, it would be premature to
exclude the importance of GABAA receptors employing alpha2
subunits in amygdala (potentially modulating the transfer of
information on conditioned events to striatum) or prefrontal
cortex. These are important questions for future study.
Finally, although there is no adequate information available
as to whether the risk and protective gene variants result in
altered levels of receptors, the parallels between the absence of
methylphenidate effects on CRf in the α2−/− mice, and humans
carrying the risk allele, suggest the effects of the risk genetic
variation may resemble that of the deletion of the GABRA2
gene in α2−/− mice. Thus, the absence of methylphenidate-
facilitation of CRf responding in humans carrying risk SNPs
for drug abuse may reflect low expression levels of α2. Some
support for this interpretation comes from a recent report
(Lieberman et al., 2015) that GABRA2 mRNA in neural cell
cultures derived from rs279858∗C allele (risk allele) carriers is
lower. If our interpretation is correct, neurotransmission through
α2-GABAARs may be protective against the development of
addictive behaviors. Enhancement of such transmission using
drugs selective for α2-GABAARs might be a novel approach to
addiction treatments. The availability of homologous human and
mousemeasures of responding for conditioned incentives should
facilitate the testing of that prediction.
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